[go: up one dir, main page]

ES487381A0 - Un procedimiento para la preparacion de un compuesto de guanidinotiazol - Google Patents

Un procedimiento para la preparacion de un compuesto de guanidinotiazol

Info

Publication number
ES487381A0
ES487381A0 ES487381A ES487381A ES487381A0 ES 487381 A0 ES487381 A0 ES 487381A0 ES 487381 A ES487381 A ES 487381A ES 487381 A ES487381 A ES 487381A ES 487381 A0 ES487381 A0 ES 487381A0
Authority
ES
Spain
Prior art keywords
guanidinotiazole
procedure
compound
preparation
guanidinotiazole compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES487381A
Other languages
English (en)
Other versions
ES8100281A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14232166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES487381(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of ES487381A0 publication Critical patent/ES487381A0/es
Publication of ES8100281A1 publication Critical patent/ES8100281A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES487381A 1979-08-02 1979-12-28 Un procedimiento para la preparacion de un compuesto de guanidinotiazol Expired ES8100281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54098906A JPS6056143B2 (ja) 1979-08-02 1979-08-02 アミジン誘導体ならびにその製造法

Publications (2)

Publication Number Publication Date
ES487381A0 true ES487381A0 (es) 1980-11-01
ES8100281A1 ES8100281A1 (es) 1980-11-01

Family

ID=14232166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES487381A Expired ES8100281A1 (es) 1979-08-02 1979-12-28 Un procedimiento para la preparacion de un compuesto de guanidinotiazol

Country Status (12)

Country Link
US (1) US4283408A (es)
JP (1) JPS6056143B2 (es)
CA (2) CA1134836A (es)
CH (1) CH648027A5 (es)
DE (1) DE2951675C2 (es)
ES (1) ES8100281A1 (es)
FR (1) FR2462431B1 (es)
GB (1) GB2055800B (es)
IT (1) IT1119641B (es)
NL (2) NL180420C (es)
PH (1) PH15657A (es)
SE (1) SE444317B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782129B (en) * 1977-04-20 1979-03-28 Ici Ltd Hertocyclic derivatives
PH16099A (en) * 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
GR71929B (es) * 1979-11-13 1983-08-19 Ici Ltd
DE3168031D1 (en) * 1980-07-30 1985-02-14 Ici Plc Guanidine derivatives
US4382090A (en) * 1980-10-02 1983-05-03 Eli Lilly And Company N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds
IN158869B (es) * 1981-03-18 1987-02-07 Ici Plc
EP0067508B1 (en) * 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Amidine derivatives
DE3238867A1 (de) * 1982-10-20 1984-04-26 Ludwig Heumann & Co GmbH, 8500 Nürnberg Heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS59104370A (ja) * 1982-12-03 1984-06-16 Kotobuki Seiyaku Kk チアゾ−ル誘導体及びその製造方法
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4497810A (en) * 1983-10-14 1985-02-05 Merck & Co., Inc. Thiatriazine dioxides as gastric anti-secretory agents
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
CA1269382A (en) * 1984-04-18 1990-05-22 Jose A. Ortiz Anti-ulceric sulfonamidines
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
JPS6160673A (ja) * 1984-08-30 1986-03-28 Yamanouchi Pharmaceut Co Ltd グアニジノチアゾ−ル誘導体の製造法
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
EP0239306B1 (en) 1986-03-27 1993-06-02 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
ES2008810A6 (es) * 1988-07-18 1989-08-01 Marga Investigacion Procedimiento de preparacion de derivados de n-sulfamil-propionamidina.
EP0480716A1 (en) 1990-10-12 1992-04-15 Merck Frosst Canada Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5667794A (en) * 1995-05-02 1997-09-16 Merck & Co., Inc. Heartburn treatment
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US5856500A (en) * 1997-03-11 1999-01-05 Albemarle Corporation Synthesis of thiazole derivatives
US5731442A (en) * 1997-03-11 1998-03-24 Albemarle Corporation Synthesis of thiazole derivatives
US6552047B2 (en) * 1998-11-17 2003-04-22 Nitromed, Inc. H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US7163705B2 (en) 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
CA2369515A1 (en) * 1999-04-06 2001-03-29 Wm. Wrigley Jr. Company Pharmaceutical chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US7935362B2 (en) 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
WO2001021147A1 (en) 1999-09-20 2001-03-29 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
WO2006071659A1 (en) * 2004-12-29 2006-07-06 Trustees Of Boston University Delivery of h2 antagonists
NZ565846A (en) * 2005-07-18 2011-12-22 Horizon Therapeutics Inc Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
DK2043637T3 (da) 2006-07-18 2012-05-07 Horizon Pharma Usa Inc Fremgangsmåder og medikamenter til administrering af ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2063873A2 (en) * 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20090069395A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched famotidine
PL2240018T3 (pl) 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US8728442B2 (en) 2009-05-11 2014-05-20 Bayer Cropscience Lp Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
WO2015002150A1 (ja) * 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
WO2015007760A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA3176466A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
WO2015155297A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
WO2015169957A1 (en) 2014-05-09 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4165378A (en) * 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles
ZA782129B (en) * 1977-04-20 1979-03-28 Ici Ltd Hertocyclic derivatives

Also Published As

Publication number Publication date
JPS5622770A (en) 1981-03-03
CA1222763B (en) 1987-06-09
GB2055800B (en) 1983-05-11
IT7969498A0 (it) 1979-12-28
CA1134836A (en) 1982-11-02
NL180420B (nl) 1986-09-16
SE7910568L (sv) 1981-02-03
NL7909321A (nl) 1981-02-04
FR2462431A1 (fr) 1981-02-13
ES8100281A1 (es) 1980-11-01
IT1119641B (it) 1986-03-10
FR2462431B1 (fr) 1985-07-26
GB2055800A (en) 1981-03-11
PH15657A (en) 1983-03-11
DE2951675C2 (de) 1982-07-01
CH648027A5 (de) 1985-02-28
US4283408A (en) 1981-08-11
NL930038I2 (nl) 1993-10-01
NL180420C (nl) 1987-02-16
DE2951675A1 (de) 1981-02-05
NL930038I1 (nl) 1993-08-02
JPS6056143B2 (ja) 1985-12-09
SE444317B (sv) 1986-04-07

Similar Documents

Publication Publication Date Title
ES487381A0 (es) Un procedimiento para la preparacion de un compuesto de guanidinotiazol
ES488154A0 (es) Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
ES489751A0 (es) Un procedimiento para la preparacion de monacolina k
AR222204A1 (es) Un procedimiento para la preparacion de derivados de i-bencilimidazol
ES489752A0 (es) Un procedimiento para la preparacion de un derivado de imi- dazolidindiona
ES495892A0 (es) Un procedimiento para la preparacion de metacroleina
ES496798A0 (es) Un procedimiento para la preparacion de un derivado de aze- tidina
ES493579A0 (es) Un procedimiento para la preparacion de derivados de triazo-lopiridazina
ES490510A0 (es) Un procedimiento para la preparacion de derivados de penici-lina
ES489470A0 (es) Un procedimiento para la preparacion de 9-aminoalquilfluore-no
ES492772A0 (es) Un procedimiento para la preparacion de un compuesto de ce- falosporina
ES491370A0 (es) Un procedimiento para la preparacion de piridizinobenzodiazepinas
ES493506A0 (es) Un procedimiento para la preparacion de desacetil-cefalospo-rina c
ES490022A0 (es) Un procedimiento para la preparacion de imidazobenzodiacepi-nas
ES490667A0 (es) Procedimiento para la preparacion de un derivado de 2-hidro-xi-5-(1-hidroxi-2-piperaciniletil)benzoico
ES499957A0 (es) Un procedimiento para la preparacion de compuestos heteroci-clicos
ES490289A0 (es) Un procedimiento para la preparacion de derivados de xantina
ES494091A0 (es) Un procedimiento para la preparacion de derivados de pirro- lidina
ES489355A0 (es) Un procedimiento para la preparacion de nuevos piretroides
ES491662A0 (es) Un procedimiento para la preparacion de un pirazol cuaterna-rio
AR222208A1 (es) Un procedimiento para la preparacion de derivados de 4-amino-2-piperidino-quinazolina
ES492539A0 (es) Un procedimiento para la preparacion de pirencepina
ES490287A0 (es) Un procedimiento para la preparacion de 2-aminopirazinas
ES489227A0 (es) Un procedimiento para la preparacion de un derivado de pira-zol
ES489878A0 (es) Procedimiento para la preparacion de un compuesto de dihalo-genovinilo